Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

By Global News Feed

QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq xHYB Custom Microbial Panels enable high-resolution sequencing by covering multiple whole genomes, overcoming coverage gaps common in standard panels QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq xHYB Custom Microbial Panels enable high-resolution sequencing by covering multiple whole genomes, overcoming coverage gaps common in standard panels

Read more here:
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

By Global News Feed

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

The rest is here:
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

By Global News Feed

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 Form 10-Q”) in a timely manner.

Original post:
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

Celularity Inc. Announces Receipt of Nasdaq Notification

By Global News Feed

FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on November 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company does not comply with the Nasdaq continued listing requirements due to the Company’s inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Q3 Form 10-Q”). Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.

Read more:
Celularity Inc. Announces Receipt of Nasdaq Notification

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

By Global News Feed

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2025 will continue to include ORPATHYS® (savolitinib) at the same terms as the current two-year agreement.

See the rest here:
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS)

By Global News Feed

BARCELONA, Spain, Nov. 29, 2024 (GLOBE NEWSWIRE) -- MEDSIR, a leading company dedicated to advancing independent clinical research in oncology on an international level, participated in the 7th Shanghai International Medical Oncology Symposium (SIMOS) in China, one of the most prestigious academic events in the global oncology field. Through this, the company reaffirms its commitment to scientific advancement, improving breast cancer treatments worldwide, and fostering the exchange of knowledge across regions.

Read more here:
MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS)

Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

By Global News Feed

VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce that, in response to investor demand, the Company intends to increase the size of the previously announced $1.25 million non-brokered private placement (the “Offering”) to $2.5 million.

See the original post here:
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

By Global News Feed

ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.

Originally posted here:
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

→←